Akkermansia Muciniphila Akk11 Strain Regulates Blood Glucose and Blood Lipid
Summary
USPTO published patent application US20260108566A1 for Akkermansia muciniphila Akk11 (deposit number CCTCC NO: M 2024119). The application claims the strain uses mucin as the sole carbon and nitrogen source to regulate glucose and energy metabolism, protecting intestinal epithelial cells and mucus layer while regulating blood glucose and blood lipid levels, with potential applications for obesity and metabolic disorder treatment. The patent application names six inventors and was filed on 2024-07-08.
“Provided are an Akkermansia muciniphila Akk11 with the effect of regulating blood glucose and blood lipid, and a use thereof.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
USPTO published patent application US20260108566A1 for Akkermansia muciniphila Akk11 (deposit number CCTCC NO: M 2024119). The application claims the strain uses mucin as the sole carbon and nitrogen source to regulate glucose and energy metabolism, protecting intestinal epithelial cells and mucus layer while regulating blood glucose and blood lipid levels, with potential applications for obesity and metabolic disorder treatment. The patent application names six inventors and was filed on 2024-07-08.
The publication makes technical details of the Akk11 strain publicly available for review. Patent application publications do not create compliance obligations for third parties. Parties interested in the technology may monitor prosecution status or evaluate potential licensing opportunities.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
AKKERMANSIA MUCINIPHILA AKK11 WITH EFFECT OF REGULATING BLOOD GLUCOSE AND BLOOD LIPID, AND USE THEREOF
Application US20260108566A1 Kind: A1 Apr 23, 2026
Inventors
Shuguang FANG, Haifeng TANG, Yao DONG, Huiyu ZUO, Zhiyi WU, Zhonghui GAI, Jianguo ZHU
Abstract
Provided are an Akkermansia muciniphila Akk11 with the effect of regulating blood glucose and blood lipid, and a use thereof. The Akkermansia muciniphila Akk11 with the effect of regulating blood glucose and blood lipid has a taxonomic name of Akkermansia muciniphila Akk11, with a deposit number CCTCC NO: M 2024119. The strain uses mucin as the only source of carbon and nitrogen elements to control the basic regulatory system of glucose and energy metabolism, which can protect the integrity of intestinal epithelial cells and mucus layer and play a metabolic protective role, regulate blood glucose and blood lipid levels, significantly improve symptoms of metabolic disorders, and provide coping strategies and references for the prevention and treatment of obesity.
CPC Classifications
A61K 35/741 A61K 35/745 A61P 3/04 A61P 3/06 A61P 3/10
Filing Date
2024-07-08
Application No.
18995618
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.